Boston Scientific Corporation (NYSE:BSX) saw an upside of 0.56% to $42.38 after adding $0.24 on Tuesday. The 5-day average trading volume is 4,203,602 shares of the company’s common stock. It has gained $44.24 in the past week. An average of 5,800,160 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 6,118,022.
BSX’s 1-month performance is -5.22% or -$2.13 on its low of $41.86 reached on 10/06/21. The company’s shares have touched a 52-week low of $32.99 and high of $46.28, with the stock’s rally to the 52-week high happening on 08/02/21. YTD, BSX has achieved 17.22% or $6.38. However, the current price is down -8.44%% from the 52-week high price.
A Backdoor Way To Profit From Today’s Crypto Bull Market
In any crypto bull market, there's a lot of money to be made.
But what if we told you the best opportunities are not cryptocurrencies themselves… but instead, simply crypto stocks?
This strategy is simply and ridiculously easy.
Here are 6 ways to gain exposure to crypto outside the norm. This is arguably the safest bet you can make.
On Oct 04, 8 days have gone by since the last insider trading activity for Boston Scientific Corporation (BSX). Mahoney Michael F (Chairman, President & CEO) most recently sold 201,042 shares at $42.92 per share on Oct 04. This transaction cost the insider $8,629,038. SVP & Pres, Rhythm Management, Olson Scott, sold 700 shares at a price of $43.49 on Oct 01. Then, on Sep 15, SVP, Human Resources Carruthers Wendy sold 3,321 shares at a price of $44.88 per share. This transaction amounted to $149,046.
The company’s PE ratio for the last five years has touched a high of 490.29 and a low of 7.757. BSX stock has a beta of 0.86. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 5.42 while the price-to-book (PB) in the most recent quarter is 3.76, with the price to cash flow ratio at 32.71.
Boston Scientific Corporation’s quick ratio for the period ended June 29 was 1.30, with the current ratio over the same period at 1.70 meaning that BSX stock is able to fulfill its debt obligations. As well, the company’s long term debt to equity for the quarter ending June 29 was 0.55, while the total debt to equity was 0.57. In terms of profitability, the gross margin trailing 12 months is 66.40%. The trailing 12-month EBITDA margin is 17.38% while for the period ending June 29; Boston Scientific Corporation’s operating margin was 4.30%. The firm’s gross profit as reported stood at $6.45 billion against revenue of $9.91 billion.
For the quarterly period ending June 29 this year, Net income and sales went up compared to those figures reported in the previous quarter. Net income grew 34.9% to $3.08 billion, while revenue of $2.75 billion was 10.56% off the previous quarter. Analysts expected BSX to announce $0.37 per share in earnings in its latest quarter, but it posted $0.4, representing a 8.10% surprise. EBITDA for the quarter stood at more than $578.0 million. BSX stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 15.23 billion, with total debt at $9.47 billion. Shareholders hold equity totaling $1.42 billion
Let’s look briefly at Boston Scientific Corporation (BSX) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 11 October was 37.63% to suggest the stock is trending Neutral, with historical volatility in this time period at 24.73%.
The stock’s 5-day moving average is $42.82, reflecting a -0.27% or -$0.11 change from its current price. BSX is currently trading -5.63% above its 20-day SMA, +0.97% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 and SMA200 by -7.75% and +22.36% respectively.
Stochastic %K and %D was 19.26% and 29.65% and the average true range (ATR) pointed at 0.95. The RSI (14) points at 39.74%, while the 14-day stochastic is at 13.14% with the period’s ATR at 0.94. The stock’s 9-day MACD Oscillator is pointing at -0.36 and -0.88 on the 14-day charts.
In the most recent analyst report for Boston Scientific Corporation (NYSE: BSX), Needham downgraded it to a Hold rating. They previously had a Buy rating on the stock. Analysts offering their rating for BSX stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate BSX as a “sell,”, while 5 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 3 rates the stock as overweight while 22 have offered a “buy” rating.
What is BSX’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $45.00 and a high of $57.00, with their median price target at $52.00. Looking at these predictions, the average price target given by analysts is for Boston Scientific Corporation (BSX) stock is $51.62.